Integumen PLC (LON:SKIN) CEO Gerry Brandon speaks to Proactive London's Andrew Scott soon after announcing the roll-out of a new Labskin test designed to clone the skin of volunteers in clinical trials.
He says the new test will cut the number of volunteers required for trials by 50%, reduce recruitment times and project management costs as well as make them more reliable and accurate.
Original Article: Integumen PLC to make 'transformational' move into clinical trials